Chicago: Significant progress is being made in the prevention and treatment of ovarian and breast cancer, according to findings discussed at a global oncology conference."The studies presented at this meeting show impressive progress in disease control and prevention of breast cancer," said Dr. Andrew Seidman, professor of medicine at Cornell University."Also, two consistent studies demonstrated the benefit of adding bevacizumab (Avastin) to standard chemotherapy for ovarian cancer," he added.Avastin, produced by Swiss biotech giant Roche, blocks the development of blood vessels needed for tumor growth.
After a period of three years, the Aromasin group had about one third as many invasive cancers as those in the placebo group -- a result corresponding to what researchers expected at the beginning of the trial, Goss said.Aromastate inhibitors like exemestane are distinct from other anti-estrogen therapies such as tamoxifen and raloxifene, which have been approved by the US Food and Drug Administration as preventative therapies for women at high breast cancer risk.Exemestane, too, has been approved by the FDA, for use in early breast cancer patients.The most common side effects reported by Aromasin users include fatigue, hot flashes, insomnia and joint pain.Also Saturday, researchers said extra radiation treatment lowers the rate of breast cancer recurring in women who have had tumors surgically removed.More than 1,800 women participated, receiving whole breast radiation (WBI) alone or WBI along with radiation to the surrounding lymph nodes.Five years later, women who received radiation treatment to the breast and lymph nodes had a 41 percent lower rate of recurrences near the tumor site and a 36 percent lower rate of cancer recurrences in other parts of the body."These results are potentially practice-changing," said Timothy Whelan, an oncology professor at McMaster University of Canada and lead author of the clinical study.Bureau Report
Single mums prone to illness in midlife
Early period leads to baby girls